AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04828954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization for 6-weeks postoperative
Description: Non-removable postoperative thumb spica splint immobilization worn for 2 weeks (+/- 3 days), to be transitioned to thumb spica cast for an additional 4 weeks (Total of 6 weeks immobilization)
Study NCT04682691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin (400mg)
Description: oral Erythromycin (400mg)
Study NCT04682691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide (10mg)
Description: oral metoclopramide (10mg)
Study NCT04682691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: naturally flavored water
Description: naturally flavored water
Study NCT06305676 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: combined HPV 16 DNA and host gene methylation oral biomarker panel
Description: DNA Methylation Profiling
Study NCT05120557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound liver assessment
Description: The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
Study NCT05414734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HHT120
Description: Capsule, oral administration
Study NCT05292651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: percutaneous coronary intervention
Study NCT05292651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: percutaneous coronary intervention
Study NCT06062446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Lumbar Puncture
Description: The Investigator will perform the modified LP procedure using the 22 Gg needles Quincke spinal needle (namely, without reinsertion of stylet into the spinal needle after cerebrospinal fluid (CSF) collection before spinal needle removal).
Study NCT04813718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omni-Biotic Pro Vi 5
Description: Pre- and probiotic
Study NCT04813718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06250140 — intervention group
Intervention type: DEVICE
Intervention: Tie up device
Description: The recurrence rate of internal hemorrhoids in different treatment methods
Study NCT05414734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, oral administration
Study NCT05131607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine MRI
Description: After completion of the standard prone MRI sequences the patient will be positioned supine, coils will be placed and baseline images will be obtained. Then a second dose of contrast equal to the first dose will be given, and additional images will be obtained
Study NCT05402826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral zinc + vitamin E
Description: In the zinc + vitamin E supplementation group, patients will receive a cumulative dose of 120 mg of oral zinc supplementation plus a cumulative dose of 1200 IU of oral vitamin E before surgery. After surgery, from the second day to the end of the hospital stay, patients receive 30 mg of zinc supplement plus 200 units of vitamin E per day.
Study NCT05402826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive placebo pills before and after surgery.
Study NCT04949932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed powder of Lens culinaris, Curcuma longa, Mentha arvensis, Azadirachta indica, and Trigonella foenumgraecum.
Description: Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
Study NCT04949932 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cicer arietinum powder
Description: Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
Study NCT05229861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants will perform five high-intensity intervals (95% HRpeak) at high pedalling rates of 80-100 rpm for 90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20W, 60-70rpm) aimed to return to 60% HRpeak (approximately 1-1.5 min). The duration of a HIIT sessions is approximately 25 minutes.
Study NCT05229861 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MCT
Description: Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants perform continuous bicycle ergometry at moderate intensity (60% HRpeak) and 60-70 rpm for the duration of 30 minutes.
Study NCT05062954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich cranberry extract supplement standardized in proanthocyanidins
Description: Participants will be randomly assigned to the consumption of one capsule of Polyphenol-rich cranberry extract standardized in PACs.
Study NCT05062954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Participants will be randomly assigned to the consumption of one capsule of placebo per day for 56 consecutive days.
Study NCT05323422 — intervention group
Intervention type: PROCEDURE
Intervention: intravenous Ketamine induction
Description: preoperatively ketamine wll administer in group 1-3
Study NCT05975853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural beat music group (BBM group)
Description: The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) with BBM embedded.
Study NCT05975853 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) without BBM embedded.
Study NCT04903600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics fruit vegetable fiber powder product
Description: Eat 16 g for once, and twice a day
Study NCT04903600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eat 16 g for once, and twice a day
Study NCT06091878 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observational study, no intervention
Study NCT05768373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Clinpro™ Fluoride Aqueous Solution
Description: Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
Study NCT05768373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M™ Vanish™
Description: Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
Study NCT05505292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: Dosed twice a day for 8 weeks
Study NCT05505292 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lifitegrast Ophthalmic Solution Vehicle
Description: Dosed twice a day for 8 weeks
Study NCT05406284 — intervention group
Intervention type: PROCEDURE
Intervention: double kissing nano culotte stenting
Description: patients with true coronary bifurcation lesion treating with double kissing nano culotte stunting technique
Study NCT06384976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101
Description: Anti-CD19 CAR-T cell therapy
Study NCT06384976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard lymphodepletion regimen
Description: CYC/FLU
Study NCT06384976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-CD20 mAB
Description: Anti-CD20 mAB
Study NCT06243562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined exercises and progressive muscle relaxation group
Description: Participants in the intervention group will receive a combined exercise program that will last 45-60 minutes, 3 days a week for 8 weeks, and progressive muscle relaxation training that will last 10-15 minutes, under the supervision of a therapist.
Study NCT06243562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined exercises group
Description: Patients in the control group will perform a combined exercise consisting of aerobic, strengthening and stretching exercises, which will last 45-60 minutes, 3 days a week for 8 weeks, under the supervision of a physiotherapist. At the end of the combined exercise program, they will rest in the relaxation position for 10-15 minutes each session.
Study NCT04915287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag maleate
Description: 1. Mean baseline platelet count 40 to less than 50 × 10\^9/L: 40mg Avatrombopag QD × 5 days from 10-13 days pre-procedure~2. Mean baseline platelet count less than 40 × 10\^9/L: 60mg Avatrombopag QD × 5 days from 10-13 days pre-procedure
Study NCT04915287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Description: Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: platelet transfusion if needed
Study NCT04915287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicine
Description: Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.
Study NCT05253417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Cannabidiol (CBD)
Description: For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.
Study NCT05253417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants take four (4) placebo capsules.
Study NCT05253417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants take four (4) placebo capsules.
Study NCT05253417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg Cannabidiol (CBD)
Description: For the study arm, '100 mg CBD' participants take four (4) CBD capsules.
Study NCT05970354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Cream
Description: Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)
Study NCT05970354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VersaPro Cream Base for Compounding
Description: Placebo
Study NCT05836298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or MINST
Study NCT05836298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or MINST
Study NCT06332508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs)
Description: Device: PEMFs~PEMFs treatment can be delivered up to 7 days prior to day of surgery (dose levels 1-2) or anthracycline-based chemotherapy (dose levels 3-4) to allow subject flexibility of timing and decrease the need for multiple visits. A research staff will be assigned to be with subject during the duration of PEMFs to monitor for any side effects during treatment.
Study NCT06332508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy
Description: Drug: Anthracycline-based chemotherapy (doxorubicin, cyclophosphamide)~At dose levels 3 and 4, two cohorts will be opened: the first cohort will undergo surgical resection immediately after completion of anthracycline-based chemotherapy, and the second cohort will undergo taxane-based chemotherapy following completion of anthracycline-based chemotherapy.
Study NCT05974982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP is a volume of autologous plasma that has a platelet concentration above baseline i.e., five times more than normal platelet counts. PRP enhances wound healing by promoting the healing process by seven growth factors present in it. They are platelet derived growth factor (αα, αβ, αβ), fibroblast growth factor, vascular endothelial growth factor, epidermal growth factor, transforming growth factor.
Study NCT05974982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy
Study NCT05242692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: Loading dose: 0.25mg/kg in 10 minutes Maintenance dose: 0.1mg/kg/h
Study NCT05242692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Loading dose: 0.2 ug/kg in 10 minutes Maintenance dose: 0.2 ug/kg/h
Study NCT05242692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Refer to either S-ketamine or Dexmedetomidine
Study NCT05058183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA
Description: Patients with stage 1 HER2 positive and triple negative breast cancer will receive ctDNA test after surgery. Treating clinicians will receive results and may change treatment plans in event of negative test.
Study NCT06273254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril and Valsartan Tablets 49mg/51mg
Description: Each tablet contains Sacubitril 49 mg and Valsartan 51 mg
Study NCT06273254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)
Description: Each tablet contains 48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex
Study NCT05212740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: The treatment will initiate with a dose of 0.5 mg/kg/day prednisolone for two weeks and the dose will halve in the next two weeks.
Study NCT05212740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise program will be performed two times per week for six weeks for 12 sessions.
Study NCT05140148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine
Description: Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease
Study NCT05140148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pills
Study NCT06465576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.
Study NCT06465576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.
Study NCT06465576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin + Mirabegron
Description: Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins.
Study NCT05136625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block
Description: A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described
Study NCT05136625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Preparation
Description: Troncular scalp blockade. Local site infiltration
Study NCT05136625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Preparation
Description: Troncular scalp blockade. Local site infiltration
Study NCT04956900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurase Wound gel
Description: Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.
Study NCT05869006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Designed SIA Instrument Supported Interpersonal Relations-Based Group Practice
Description: Group Practice
Study NCT05869006 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group practice
Description: The placebo control group application was carried out simultaneously with the intervention group application, and the group application without active curative content was applied.
Study NCT05193279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Study NCT05035680 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Unadjuvanted seasonal influenza vaccine
Description: Single 0.5 mL IM injection
Study NCT05035680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SWE adjuvant mixed with unadjuvanted seasonal influenza vaccine shortly before dosing (SWE + QIV)
Description: Single 0.8 mL IM injection
Study NCT05035680 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59 adjuvanted seasonal influenza vaccine
Description: Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
Study NCT05376007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious game 'Broodles'
Description: The serious game 'Broodles' is a newly developed web-based, educational game that can be played by siblings on a computer or tablet without support from an adult. The game discusses the nine domains of sibling quality of life (Moyson \& Roeyers, 2012) in eight 20-minute levels. The main characters of the game are the Broodles, which are little monster creatures that experience things that siblings of children with ID and/or VI can also experience. The game includes animations, videos of siblings talking about their experiences, quizzes and mini-games. These elements are focussed on emotions, thoughts and difficult situations that siblings can experience. In addition to the game, siblings make offline worksheets and parents receive an information brochure. Siblings complete the game in four weeks.
Study NCT05627778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-11. Tracer doses of 68Ga- PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
Study NCT05627778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-P15-041
Description: Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P15-041. Tracer doses of 68Ga- 15-041 will be used to image lesions of prostate cancer by PET/CT.
Study NCT05183828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of saliva samples
Study NCT05183828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT06024525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Coated Coronary Balloon Catheters
Description: to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
Study NCT06024525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-Releasing Coronary Balloon Catheters
Description: to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
Study NCT04742673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.
Study NCT04742673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.